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Stlmlllary 
We have characterized the immunobiology of the interaction of intercellular adhesion molecule 
3 (ICAM-3; CD50) with its counter-receptor,  leukocyte function-assodated antigen 1 (LFA-1; 
CDlla/CD18). Purified ICAM-3 supported LFA-l-dependent adhesion in a temperature- and 
cation-dependent manner. Activation of cells bearing LFA-1 increased adhesiveness for ICAM-3 
in paralld to adhesiveness  for ICAM-1. Although CBR-IC3/1 monodonal antibody (mAb) blocked 
adhesion of ceUs to purified LFA-1, when tested alone, neither CBR-IC3/1 nor five novel ICAM-3 
mAbs characterized here blocked adhesion of cells to purified ICAM-3 or homotypic adhesion. 
Two ICAM-3 mAbs, CBR-IC3/1 and CBR-IC3/2, were required to block LFA-l-dependent 
adhesion to purified ICAM-3- or LFA-l-dependent, ICAM-I-, ICAM-2-independent homotypic 
adhesion of lymphoid cell lines. Two ICAM-3 mAbs,  CBR-IC3/1 and CBR-IC3/6, induced 
LFA-l-independent aggregation that was temperature and divalent cation dependent and was 
completely inhibited by ICAM-3 mAb, CBR-IC3/2,  recognizing a distinct epitope.  Purified 
ICAM-3 provided a costimnlatory signal for proliferation  of resting T  lymphocytes,  mAb to 
ICAM-3, together with mAbs to ICAM-1 and ICAM-2, inhibited peripheral blood lymphocyte 
proliferation in response to phytohemagglntinin, allogeneic stimulator celLs, and specific antigen. 
Inhibition was almost complete and to the same level as with mAb to LFA-1, suggesting the 
most functionally important, and possibly all, of the ligands for LFA-1 have been defined. 
L 
ukocyte cell surface adhesion molecules play an essential 
role in inflammatory and immune responses (1, 2). These 
adhesive  interactions  are  mediated  in  part  by  leukocyte 
function-associated antigen-1 (LFA-1)  1 and its ligands, inter- 
cellular adhesion molecules (ICAM)-I, ICAM-2, and ICAM-3 
(2-5). LFA-1 has been shown to be involved in a wide va- 
riety of cell-ceU  interactions, induding T cell-mediated killing, 
T helper and B lymphocyte responses, natural killing, Ab- 
dependent cellular cytotoxicity by monocytes and grannlo- 
cytes, and adherence of lenkocytes to endothelial cells, fibro- 
blasts, and epithdial cells (6-8). 
The LFA-1 counter-receptors,  ICAM-1,  ICAM-2,  and 
ICAM-3, have been identified and shown to be type I mem- 
brane glycoproteins  that are members of the immunoglob- 
ulin superfamily (3-5, 9-14).  ICAM-1 contains five Ig-like 
domains (15, 16), whereas ICAM-2 contains only two Ig- 
like domains (3). The two Ig-like domains of ICAM-2 are 
36% identical at the amino acid level to the first two Ig-like 
1 Abbreviations used in this paper: HbsAg,  hepatitis  B  surface antigen; 
ICAM,  intercellular  adhesion  molecule;  LFA-1, leukocyte  function- 
associated antigen 1. 
domains of ICAM-1, to which the LFA-1 binding site has 
been mapped (17, 18). 
The third LFA-1 counter-receptor, ICAM-3, was identified 
by a mAb that inhibited binding of lymphoblastoid cells to 
purified LFA-1 (5). ICAM-3 is a heavily glycosylated glyco- 
protein of 124,000 Mr that is well expressed on lenkocytes, 
and absent on endothelham.  Cloning of ICAM-3 revealed 
that it contains five Ig-like domains that are highly homolo- 
gous to the corresponding domains in ICAM-1 and ICAM-2 
(12-14).  ICAM-3  shares  52%  amino acid  identity with 
ICAM-1, while the first two NHz-terminal Ig-like domains 
of ICAM-3 have 37% amino acid identity to the two Ig-like 
domains of ICAM-2. Last, ICAM-3 and CDS0, a molecule 
defined by its cell distribution in the Fourth International 
Leukocyte Workshop, were found to be identical  (19). 
Despite the homologies between the ICAMS, their pat- 
terns of expression suggest specialized roles (5). The finding 
that adhesion of resting T  lymphocytes to purified LFA-1 
occurs primarily via ICAM-3 (5), combined with the fact 
that ICAM-3 is much better expressed than other LFA-1 
ligands on monocytes and testing lymphocytes, suggested that 
ICAM-3 might be important in the initiation of immune 
responses. ICAM-3 could potentially be important in lyre- 
619  J. Exp. M.ed. ￿9  The Rockefeller University Press ￿9 0022-1007/94/02/0619/11  $2.00 
Volume 179  February 1994  619-629 phocyte activation, as well as in adhesion.  T  call activation 
through TCR cross-linking is insufficient by itsdf, and re- 
quires "accessory" signals that are provided by the conjuga- 
tion of numerous adhesion molecules (20-23).  Ligand en- 
gagement of LFA-1, through ICAM-1 (24, 25) or ICAM-2 
(26), has been shown to act as a costimulus with CD3 mAb 
cross-linking of the TCK, resulting in cell proliferation and 
IL-2 secretion. 
Here we characterize the immunobiology of the ICAM- 
3/LFA-1  interaction.  Although  the  previously  described 
ICAM-3 mAb was effective at inhibiting ICAM-3 adhesion 
to purified LFA-1 (5), it was unable, in combination with 
ICAM-1 and ICAM-2 mAbs, to inhibit PMA-induced SKW3 
aggregation.  Further mAbs to ICAM-3 were obtained that 
completely inhibit homotypic aggregation, and ICAM-3 was 
purified for use in functional studies. Purified ICAM-3 was 
found to support LFA-l-dependent adhesion, and also to be 
capable of providing a costimulatory signal to resting T lym- 
phocytes. ICAM-3 was shown to be important in PBL prolifer- 
ation in response to PHA, and in allogeneic and antigen specific 
proliferation, and comparison of inhibition by ICAM-1, -2, 
and -3 mAbs with LFA-1 mAb does not provide any evi- 
dence for a further  ICAM. 
Materiah  and Methods 
Monoclonal Antibodies.  The following previously described mu- 
fine mAbs to human antigens were used: W6/32 (anti-HLA, A, K 
C, IgG2a) (27), G10-2 (anti-CD43, IgG1) (28), (319-1 (anti-CD43, 
IgG1) (28), TS2/9 (anti-LFA-3, I8G1  ) (29), TS2/18  (anti-CD2, 
IgG1) (29), TS1/18 (anti-CD18, IgG1) (29), TS1/22 (anti-CD11a, 
IgG1) (29), RR1/1 (anti-ICAM-1,  IgG1) (9), CBR-IC2/2 (anti- 
ICAM-2, IgG2a) (4), CBR-IC3/1 (anti-ICAM-3,  IgG1) (5), and 
X63 (nonbinding  antibody,  IgG1). 
Generation of additional mAbs to ICAM-3 was based on a pre- 
viously published protocol (30). In brief, 3-12-wk-old BALB/c fe- 
male mice (Charles River Laboratories, Wilmington,  MA) were 
immunized with purified ICAM-3 in adjuvant (2 ~g/immuniza- 
tion) three times at 3-wk intervals. 3 d before fusion with the mu- 
fine mydoma, the mice were injected both intraperitoneally  and 
intravenously with purified ICAM-3. The protocol for fusion and 
subsequent maintenance of hybridomas was as previously described 
(31). Initial screening of hybridoma supematants  was performed 
by ELISA against purified ICAM-3 absorbed onto plastic. Reac- 
tive  hybridoma  supernatants  were  then  tested  by indirect  im- 
munofluorescence flow cytometry for reactivity to ICAM-3-bearing 
SKW3 cells and neutrophils. Of 500 hybridomas supernatants,  5 
mAbs (CBR-IC3/2,  IgG2a;  CBR-IC3/3,  IgG2a;  CBR-IC3/4, 
IgM; CBR-IC3/5, IgGa; CBR-IC3/6, IgE) tested positive in both 
primary and secondary screens, immunoprecipitated  a protein of 
124,000 M, from 12SI-hbded SKW3 lysates, and reacted specifically 
to COS cell transfectants expressing ICAM-3.  Hybridomas were 
cloned three times by limiting dilution and isotyped by ELISA using 
fffinity-purificd antibodies to mouse Igs (Zymed Immunochem- 
icals, San Francisco, CA). All mAbs were used at a saturating con- 
centratiun of 20/~g/ml for adhesion assays, excepting mAb CBIK- 
IC3/6, which was used as a 1:200 dilution of mAb-containing  as- 
cites fluid. 
Cell Culture.  The murine mydoma, P3X63Ag8.653, and sub- 
sequent hybridomas were maintained as previously described (4). 
COS cells and human lymphoid cell lines were grown in RPMI 
1640 supplemented with 10% FCS, 5 mM glutamine, and 50/~g/ml 
gentamycin at 37~  in the presence of 5% CO2. 
Isolation of PBMC was as described (4). PBL were enriched by 
incubating PBMC on tissue culture-treated plastic petri dishes twice 
for 1 h each and saving the nonadherent  cells. For costimulation 
assays, resting CD3 § T lymphocytes (95% CD2 § , 99% CD3 § 
were purified from PBL through two rounds of rigorous immuno- 
magnetic-negative  selection  using  Dynabeads  M-450  (Dynal; 
Robbins Scientific, Mountain  View, CA) and mAbs specific for 
CD14, CD16, CD20, Mac-l, and HLA-DR. The purified T lym- 
phocytes were functionally assessed to be depleted of monocytes 
by the criterion that there was no proliferative response to optimal 
concentrations  of PHA-M (1:200 dilution;  Gibco Laboratories, 
Grand Island, NY). 
Protein Purification.  LFA-1, ICAM-1,  and  LFA-3 were  puff- 
fled from JY lysates as previously described (11, 32, 33), while 
the ICAM-3  purification from SKW3 lysates was adapted from 
a previously published protocol (12). Proteins were purified from 
detergent  lysates of JY or SKW3 cells by immunoaflinity  chro- 
matography  using  TS2/4  (LFA-1), RR1/1  (ICAM-1),  TS2/9 
(LFA-3), or  CBR-IC3/1  (ICAM-3)  mAb-coupled  Sepharose. 
The immunoaffmity  column-bound proteins  were eluted  with 
either  50 mM triethylamine,  pH  11.5, 150 mM NaCI,  2 mM 
MgClz, 1% ocytyl-fl-D-glucoside (OG) (LFA-1), 50 mM trietbyl- 
amine, pH 12.5, 150 mM NaCI, 1% OG (ICAM-1), 50 mM gly- 
due, pH 3.0, 150 mM NaCI, 1% OG (LFA-3), or 50 mM glyeine, 
pH 3.8, 150 mM NaCI, 1% OG (ICAM-3). Samples were neutral- 
ized, aliquoted, and stored frozen at  -70~  for 3-6 mo without 
loss of activity Aliquots of the neutralized fractions (10 ~1) were 
subjected to SDS-7.5% PAGE (34) under reducing conditions and 
silver stained (35). 
eDNA and Traasfection.  LFA-lo~  and fl cDNAs in the transient 
exprmsion vector CDM8 (36, 37) or vector alone (mock) were trans- 
fected into COS cells using DEAE-dextran (38). 3 d after transfec- 
tion, cells were detached with 10 mM EDTA/HBSS, washed three 
times in 10% FCS/RPMI 1640, and then used for binding to LFA- 
1-coated plates. A~jndged by indirect immunofluorescence, 30-50% 
of LFA-I~x/fl eDNA transfectants expressed LFA-1 on their cell 
surfgce. 
Adhesion  Assay.  Purified  ligand  (LFA-1, LFA-3, ICAM-1, 
ICAM-3) in 1% OG was diluted in 25 mM Tris HCI, pH 8.0, 
150 mM NaC1, 2 mM MgClz (TSM), and absorbed onto either 
96-well plates or 60-mm petri phtes as previously described (4, 39). 
The number of ligand sites per microtiter wen was determined using 
saturating  amounts  of lzsI-labeled mAb  (LFA-1, mAb TS1/22; 
ICAM-1, mAb RR1/1; ICAM-3,  mAb CBR-IC3/1) and calcu- 
lated assuming monovalent binding of the mAb (40). Site numbers 
are expressed per square micron;  the surface area of a microtiter 
well and the area of purified protein occupied by a 25-/~1 spot on 
a petri plate were identical, being 3.85  x  107/~m  z. 
Adhesion of cells fluorescently labeled with 2',7'-bis-(2-carboxy- 
ethyl)-5(and-6) car~uorescein (BCECF; Molecular Probes, Inc, 
Eugene, OR) to 96-well phtes coated with purified ligand was per- 
formed as previously described (4, 5). For inhibition,  wells con- 
t~ining immob'~.ed purified protein were incubated with 20/tg/ml 
of the appropriate purified mAb(s) for 45 rain at room tempera- 
ture, or labeled cells were resuspended in assay buffer (PBS, 5% 
FCS, 2 mM MgC12), pretreated  with 20/~g/ml  of appropriate 
purified mAb(s) for 45 rain  at 4~  and either  5  x  10' (COS 
transfectants) or 10  s (cell lines) cells were transferred to each well. 
After 1 h at 37~  nonadherent  ceils were removed with either 
four 25-gauge (COS calls) or six 23-gauge (cell lines) needle aspi- 
rations. Bound cells were quantitated  in the 96-well plate using 
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brook,  ME). 
Adhesion of cells to ligand-spotted petri plates was performed 
as previously  described  (I8, 39, 41). For inhibition, petri plates con- 
taming immobilized purified protein were incubated with I ml of 
a 20-/~g/ml  solution of the appropriate purified mAb(s) for 45 min 
at room temperature. Alternatively, cells (2  x  106 cells/ml) were 
resuspended in assay  buffer and incubated with appropriate mAbs 
for 45 rain at 4~  CeUs were then added (2  x  106 cells) to a 
60-mm petri plate and adhered for 60 rain at 37~  For phorbol 
ester stimulation, cells  were  incubated  with incubated  with 50 ng/nd 
PMA upon addition to the petri plates. Unbound ceils were re- 
moved  by six washes  with a transfer  pipette. Bound cells were quan- 
titated by visually scoring the number of cells in six microscopic 
fields (x 100). This number was divided into the input number of 
cells, which was determined in parallel to obtain percentage of cell 
binding. Homotypic aggregation did not occur in this assay; it re- 
quires 3-5 h to be detectable. Visual inspection confirmed that in- 
creased adherence of cells to LFA-1 stimulated by PMA was the 
result of increased adherence of single cells, rather than to forma- 
tion of aggregates. 
Costimulation Assa7~  Cosfimulation assays  using coimmobilized 
ligand and anti-CD3 mAb were performed as described previously 
(24). Preparation  of  flat-bottomed  96-well tissue  culture phtes (3596; 
Costar, Cambridge, MA) with varying  concentrations  of  coimmobi- 
lized ICAM-3 and CD3 mAbs (OKT3) was adapted from a previ- 
ously published protocol (24). Site densities of ICAM-3 were de- 
termined as described above; success  ofCD3 mAb immobilization 
was determined using 12SI-labeled rabbit anti-mouse IgG (Zymed 
Labs., Inc., S. San Francisco, CA). Resting T lymphocytes (5  x 
104/well), with appropriate mAbs, were cultured for 3 d in RPMI 
4640 supplemented  with 10% heat-inactivated  FCS (Hyclone  Labs., 
Logan, UT), 5 mM glntamine, and 50/~g/ml gentamyvin. Cells 
were incubated at 37~  in a 5% CO2 humidified atmosphere, 
and pulsed for 8 h before harvesting on day 3 with 1/~Ci/well 
of [3H]thymidine 0.3 Ci/mM; New England Nuclear, Boston, 
MA). Incorporation of radioactive label was measured by liquid 
scintillation counting, and results were expressed  as the arithmetic 
mean counts per minute of triplicate cultures. 
/~o//f~t/on A~.  Proliferation  in response to PHA, allogeneic 
stimulator cells (MLR), or recombinant hepatitis B surface  antigen 
(HbsAg) was as previously described (42, 43). Briefly, 10  ~ PBL, 
and appropriate mAbs, were seeded  in a volume of  200/zl of  RPMI 
1640 supplemented  with 10% heat-inactivated  FCS (Hyelone  Labs), 
5 mM glutamine, and 50/~g/ml gentamycin into each well of a 
96-well flat-bottomed microtiter plate. PBL for HBsAg-dependent 
proliferation  were taken from donors who had been boosted within 
2-3 wk. Recombinant HBsAg, flee of  preservative, was a gift from 
Dr. C. Alper (Center for Blond Research, Boston, MA). Cells were 
activated  with a 1:200 to 1:1,600 dilntion of  PHA-M (Gibeo  Labora- 
tories), 0.5  x  10  s or 0.2  x  10  s allogeneic PBMC  that were 
mitomycin C treated (50/~g/ml; Sigma Chemical Co.) for 20 rain 
at 37~  (MLR), or 0.1-1/~g/ml recombinant HBsAg (0.02-0.2 
/~g I-IBsAg/well). Cells were incubated at 37~  in a 5%  CO2 
humidified atmosphere, and pulsed for  18  h before harvesting 
(PHA, day 3; MLR, day 5; HBsAg, day 5) with 1/,~Ci/well of 
[3H]thymidine (3.3 Ci/mM; New England Nuclear). incorpora- 
tion  of radioactive label was  measured by liquid  scintillation 
counting, and results were expressed as the arithmetic mean counts 
per minute of triplicate cultures. 
Aggregation  Assay.  Qualitative aggregation assays  were carried 
out as described (44). Briefly, 50/~1 of a SKW3 cell suspension 
(2 ￿  10~/ml)  in 10% FCS/RPMI 1640 was preincubated with 20 
/~g/ml of purified mAb or 1:200 dilution of ascites for 45 rain at 
room temperature. These cells  were then stimulated with 50 ng/rrd 
of  PMA and added to a flat-bottomed 96-well microtiter plate well 
(Becton Dickinson  & Co.,  Lincoln Park,  NJ). mAb-induced aggre- 
gation was identical, except cells were directly placed in wells in 
the absence  of  PMA and allowed  to aggregate. Cells were incubated 
for either 1-2 h (mAb) or 4-6 h (PMA) at 37~  viewed with 
an inverted microscope, and scored visually. Photomicrographs of 
aggregating cells were taken using a Nikon Diaphot-TMD inverted 
microscope (Nippon Kogaku, Tokyo, Japan) and phase contrast 
optics. 
Results 
Functional Studies with a Panel  of  lCAM-3 raAhs.  We pre- 
viously obtained a single ICAM-3 mAb, CBR-IC3/1  (5). 
Eve further mAbs to human ICAM-3 were obtained using 
purified ICAM-3 as immunogen, as described in Materials 
and Methods. Each mAb was tested alone or in conjunction 
with mAbs to ICAM-1 and ICAM-2 for its ability to inhibit 
adhesion of SKW3 cells to purified LFA-1 (Fig.  1). In addi- 
tion to mAb CBR-IC3/1, only mAb CBR-IC3/6 was capable 
of inhibiting ICAM-3  interactions with purified LPA-1. 
Blocking with CBR-IC3/1 and CBR-IC3/6 was partial when 
used alone, and essentially complete when used with mAbs 
to  ICAM-1  and ICAM-2,  consistent with expression by 
SKW3 ceils of all three ICAMs (5). 
Evidence for LFA-1 counter-receptors that were distinct 
from ICAM-1 was first obtained with PMA-stimuhted homo- 
typic aggregation of the SKW3 T lymphoma  cell llne, which 
was inhibited with LFA-1 mAb but not with ICAM-1 mAb 
(9). Combination of  function-blocking ICAM-1 and ICAM-2 
mAbs also does not inhibit SKW3 PMA-induced aggrega- 
I00. 
80 
Alone  With RRI/I + CBR-IC2/2 
mAb pretreatment 
￿9  No mAh 
[]  TS1/22 
[]  CBR-IC3/I 
[]  CBR-IC3/2 
[]  CBR-IC3/3 
￿9  CBR-IC3/4 
CBR-IC3/5 
[]  CBR-1C3/6 
mAb Combinations 
Figta'e 1.  Effect  of anti-ICAM-3 mAbs on adhesion  of SKW3 cells to 
purified  LFA-1.  Cells  were pretreatcd  with saturating  concentrations  of 
one  of  six  ICAM-3 mAbs in  the  presence  or  absence  of  blocking  ICAM-I 
(RKI/I) and ICAM-2 (CBK-IC2/2) mAbs, allowed  to bind  to LFA-1- 
coated microtiter wells for 60 min at 37~  and then washed six times 
by aspiration. Altemativdy,  the absorbed purified  LFA-1 was pretrcated 
with LFA-lc~  mAb (TS1/22). Site density  of LPA-1 as determined  by ra- 
dioimmunoassay  was  700 sites//zm  2,  One representative  of  three  is  shown 
and bars show one slandard deviation. 
621  de IbugerolIes  et zl. tion (4).  None of the ICAM-3 mAbs were capable of in- 
hibiting PMA-induced aggregation by themselves or in com- 
bination with ICAM-1 and ICAM-2 mAbs (Table 1). Indeed, 
mAbs CBR-IC3/1 and CBR-IC3/6 actually promoted aggre- 
gation (see below). Aggregation was, however, completely 
inhibited when certain combinations of anti-ICAM-3 mAbs 
were used in conjunction with ICAM-1 and ICAM-2 mAbs 
(Table 1). One such example was when CBR-IC3/2  mAb 
was used in conjunction with CBK-IC3/1 mAb (Table 1). 
The combination of CBR-IC3/1 and CBK-IC3/2, along with 
ICAM-1 and ICAM-2 mAbs, was capable of complete inhi- 
bition of PMA-induced aggregation of SKW3 cells, to the 
level seen with LFA-1 mAbs (Table 1). ICAM-3 antisera de- 
rived from mice immunized with purified ICAM-3, if used 
in the presence of ICAM-1 and ICAM-2 mAbs, also com- 
pletely inhibited PMA-induced SKW3 aggregation (data not 
shown). 
Two mAbs to ICAM-3,  CBR-IC3/1  and CBR-IC3/6, 
promoted SKW3 homotypic aggregation (Fig. 2, B and C). 
Induction of aggregation occurred within 1-2 h in both PMA- 
stimulated and unstimulated SKW3 cells.  Aggregation of 
SKW3 cells in the absence of PMA is very noticeable, as these 
cells normally do not display any spontaneous aggregation 
(Fig.  2 A).  None of the four mAbs to ICAM-3,  nor Fab 
fragments of mAb CBK-IC3/1,  induced aggregation. The 
presence of mAb CBR-IC3/2 prevented both CBR-IC3/1- 
and CBR-IC3/6-induced aggregation (Fig.  2 D,  and data 
not shown). It is interesting that the two mAbs that blocked 
binding to purified LFA-1 were the same mAbs that stimu- 
lated aggregation. It seemed unlikely that Fc receptors were 
involved, since CBR-IC3/1  and CBR-IC3/6  are IgG1 and 
IgE, respectively. Furthermore, aggregation was absent at 4~ 
or when performed in the presence of 5 mM EDTA (data 
not shown), seemingly suggestive of an integrin interaction 
rather than simple crossbridging effects of the mAb. A va- 
riety of mAbs to other adhesion structures, including VLA 
(c~1-6), CD29  (B1), LFA-1,  Mac-l,  p150,95,  CD18  (/~2), 
CD2,  LFA-3,  /~4, and B7,  had no effect on this adhesion 
(data not shown). ICAM-3 mAb-induced aggregation was 
not restricted to SKW3 cells, as it occurred with a variety 
of cells, including the CD18-deficient cell line SLA (data not 
shown). 
Adhesion to Purified ICAM-3.  To better elucidate ICAM-3 
function as an LFA-1 ligand, we compared LFA-l-dependent 
binding to purified ICAM-1 and ICAM-3. PMA-stimulated 
SKW3 cells bound to purified ICAM-1 and ICAM-3 in a 
LFA-l-specific manner (Fig. 3). No morphological differences 
were observed in cells binding to either purified ICAM (data 
not shown). Adhesion was completely inhibited by LFA-lc~ 
and CD18 mAbs (Fig. 3). Adhesion to purified ICAM-3 was 
not blocked with either CBR-IC3/1 or CBR-IC3/2 mAbs 
alone, but only when the two were used together (Fig.  3 
A). Contrary to a report of CD43 interaction with ICAM-1 
(45), SKW3 adhesion to purified ICAM-1 and ICAM-3 was 
not only completely LFA-1 specific, but also was not inhibited 
with CD43 mAbs (Fig.  3 B). Specificity of the interaction 
was further proved through adhesion assays using cDNA trans- 
fectants (Fig. 4).  COS cells transiently transfected with ei- 
ther cDNA for both ol and fl chains of LFA-1 (CD11a, CD18) 
or only transfected with ot chain cDNA (mock) were allowed 
to adhere to purified ICAM-1 and ICAM-3 (Fig.  4). Mock 
transfectants did not adhere to either purified protein, while 
transfectants expressing LFA-1 bound to ICAM-1 and ICAM-3 
in a LFA-1 mAb-inhibitable manner. Similarly, SLA, a cell 
line derived from a LFA-l-ddicient patient (46), did not ad- 
here to either ICAM-1  or ICAM-3  (data not shown). 
To test whether the activity of LFA-1 for ICAM-3 could 
be regulated by PMA, as has been previously demonstrated 
for ICAM-1, cells treated with or without PMA were as- 
sayed for binding to purified ICAM-3 (Fig.  5).  Binding to 
ICAM-3 was enhanced fivefold by PMA stimulation, while 
binding to ICAM-1 was also enhanced, as previously reported 
(32,  47).  Adhesion to purified ICAM-1 and ICAM-3 was 
specific as it was inhibited by the pretreatment of cells with 
an LFA-1 mAb, TS1/22. PMA treatment of SKW3 cells also 
resulted in a threefold increase in binding to purified LFA-3 
Table  1.  Effect  of ICAM-3  mAbs on PMA-induced SKW3 Aggregation in the Presence of ICAM-I  and ICAM-2 raAbs 
mAb  CBK-IC3/1  CBR-IC3/2  CBR-IC3/3  CBK-IC3/4  CBR-IC3/5  CBR-IC3/6 
CBR-IC3/1  3  0  0  0  0  5 
CBR-IC3/2  3  3  1  3  0 
CBR-IC3/3  3  3  3  1 
CBR-IC3/4  2  3  2 
CBR-IC3/5  3  1 
CBR-IC3/6  5 
SKW3 cells were preincubated at room temperature  for 45 min with one or combinations of any two ICAM-3 mAbs, in the presence of ICAM-1 
(RK1/1) and ICAM-2 (CBR-IC2/2) mAbs. Cells were stimulated with 50 ng/ml PMA, and aggregation  was scored visually after 5 h. 0, no cells 
clustered;  1, <10% of cells aggregating;  2,  10--50% of cells aggregating;  3,  50-100% of cells aggregating;  4,  nearly 100%  of cells in loose ag- 
gregates;  5,  100%  of cells in very compact aggregates.  Cells aggregated  in the absence of mAbs (score 4),  and in the presence of only ICAM-1 
and ICAM-2 mAbs (score 3).  Aggregation was not inhibited by ICAM-3 mAbs alone (score 4); LFA-1 mAbs completely inhibited aggregation 
(score 0).  One of two representative experiments  is shown. 
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|CAM-I  ICAM-3  ICAM-1  ICAM-3 
Purified Ligand 
Figure 3.  Binding of PMA-stimuhted SKW3 cells to 
purified ICAM-1 and ICAIVb3. (A) SKW3 cells (2 x  106 
cells/nil) were incubated in the presence of either no mAb 
or mA~ ~1/22 and ~1/18 (anfi-LFA-lo~  and anfi-CD18) 
or, altermti~ly, the absorbed  purified  ICAM-1 and ICAM-3 
was ptetreated with either mAb RK1/1 (anti-ICAM-1), 
mAb CBK-IC3/1 (anti-ICAM-3), mAb CBK-IC3/2 (anti- 
ICAM-3), or mAbs CBK-IC3/1 and CBK-IC3/2 (anti- 
ICAM-3). (B) SKW3 cells (2  x  106 cells/m1)  were incu- 
bated in the presence of cuntrol mAb T$2/18 (anti-CD2), 
mAbs TS1/22 and TS1/18 (anfi-LFA-la  and anti-CD18), 
mAbs G10-2 and G19-1 (anti-CIM3), or mAbs TSI/22, 
TS1/18, G10-2, and G19-1 (anti-LFA-l~t, anti-CD18, and 
anti-CD43).  SKW3 (2  x  10~ cells) were then added to 
an equal volume of assay  bufl~ cont~uing 100 ng/ml PMA 
in 60-ram petri,~d,  es coated with spots of putib~ ICAM- 
1 and ICAM-3, and incubated for 60 min at 37~  Un- 
bound cells were removed by six washes with a transfer 
pipette. The ICAM-1 and ICAM-3 site densities were de- 
termined by radioimmunoassay  to be  1,400 sites/#m  2 
each. One of three (.4) or two (B) representative experi- 
ments is shown and bars show  1 SD. 
(Fig. 5). Adhesion to LFA-3 was completely inhibited with 
the LFA-3 mAb, TS2/18 (data  not shown). These results 
confirmed an earlier report that described increased adhesive- 
ness of CD2 for LFA-3 in response to phorbol ester stimula- 
tion (48). 
SKW3 cells bound to both purified ICAM-1 and ICAM-3 
in a site density-dependent manner (Fig.  6).  The level of 
binding of unactivated cells to purified ICAM-1 was higher 
than that previously published (32); this was due to the lower 
stringency washing conditions used in this adhesion assay. 
ICAM-1/LFA-1 interactions were previously shown to be 
both temperature and cation dependent (11). Adhesion of LFA- 
1-bearing cells to purified ICAM-1 and ICAM-3 was cation 
[] 
m 
50 
t  COS cell t rm~ectant 
40t  7  []MOCK  []  [,FA-I 
30 
20 
10 
ICAM-I  ICAM-3  ICAM-I  ICAM-3 
(No  mAb treatm4mr  ('1~1/22  mAb t~atm~JO 
Purified Ligand 
Figure 4.  LFA-l-~cpressing COS cell tr~nsfectants adhere specifically 
to purified ICAM-1 and ICAM-3. Mock or LFA-l-transfected COS cells 
(8  x  10  s cells/ml) were incubated in the presence of either no mAb or 
mAb TS1/22 (anti-LFA-lr~). COS transfectants (8 x  10  s cells) v,~re then 
211owed to bind in the presence of PMA to spots of purified ICAM-1 and 
ICAM-3, exactly as in Fig. 3.  One of three representative experiments 
is shown and bars show 1 SD. 
dependent (Fig. 7 A). Removal of Mg  2  + resulted in loss of 
binding to both purified ICAM-1 and ICAM-3. Maximal 
adhesion of LFA-l-bearing cells to purified ICAM-1  and 
ICAM-3 was seen at 37~  with decreeing binding at lower 
temperatures (Fig. 7 B). No binding was seen to either purified 
ICAM-1 or ICAM-3 at 4~  and only minimal binding was 
seen to ICAM-1 at  16~ 
Costimulation via ICAM-3.  Purified ICAM-3 coimmobi- 
lized with CD3 mAb resulted in a strong proliferative signal 
(Fig. 8 A). This costimulatory activity was present at several 
concentrations of CD3 mAb and several ICAM-3 site densi- 
ties, whereas CD3 mAb or purified ICAM-3 alone did not 
result in any proliferative signal. This proliferative response 
was completely inhibited in the presence of appropriate LFA- 
loL, LFA-1/3, and ICAM-3 mAbs (Fig. 8 B). The require- 
ment for TCK cross-linking in delivering a costimuhtory 
signal is demonstrated by the inability of soluble CD3 mAb 
and immobilized ICAM-3 to result in a proliferative response 
(Fig. 8 B). Purified ICAM-1 coimmobilized  with CD3 mAb 
also resulted in a significant proliferative response, consistent 
with previous results (24,  25),  while coimmobilization of 
purified LFA-1 and CD3 m.Abs  had no effect (data not shown). 
Role of lCAMs in Immune Responses.  To test the hypoth- 
esis that ICAM-3 plays an important role in the initiation 
120  _ 
100_ 
80  _ 
60 
Cet! pretreatment 
￿9  Nt~ PMA-  No mAb  [] NO PMA-  TS1/22  [] PMA-  NO  mAb  [] PMA-  TSI/22 
40~ 
20 
J 
t). 
IOAM-I  IC AM-3 
Purified  Ligand 
LFA-3 
Figure s.  PMA-ind,_,,:~_bind- 
ing to puri~ed LFA-3, ICAM-1, 
and ICAM-3. SKW3 cens (2  x 
106 cells/ml)  were  incubated  in 
the presence of either no mAb or 
mAb T$1/22 (anti-LFA-la), and 
allowed to b~nd  in the presence or 
absence  of 50 ng/ml PMA to spots 
of purified ICAM-1 and ICAM-3, 
~ctly as described in Fig, 3. One 
of three tepresencafve  experiments 
is shown and bars show 1 SD. 
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Figure  6.  Effect of PMA stimulation on SKW3 binding to different 
densities of ICAM-1  and ICAM-3. SKW3 cens were added to an equal 
volume of either binding buffer alone or binding buffer COntaining  100 
ng/ml PMA,  and allowed  to bind to petri dishes coated with spots of 
purified ICAM-1 and ICAM-3, as described in Fig. 3 legend. Site densities 
were determined by radioimmunoassay. One of three representative ex- 
periments is shown and bars show 1 SD. 
of immune responses, the relative importance of each ICAM, 
separately and in various combinations,  was tested in a va- 
riety of immunological assays (Fig. 9). Proliferation to PHA 
(Fig. 9 A) was inhibited by LFA-1 mAb TS1/22,  as previ- 
ously  described (42).  ICAM-1  mAb  showed  little effect, 
whereas ICAM-2 and ICAM-3 mAbs, when used alone, each 
significantly inhibited proliferation. Treatment of cells with 
mAbs to two of the ICAM molecules resulted in further in- 
creased inhibition of proliferation in response to PHA. mAbs 
to all three ICAM molecules reduced the PHA-proliferative 
response to levels equivalent to when no PHA was added. 
As previously reported (42),  anti-LFA-1 and anti-CD18 
mAbs ef~dendy inhibited proliferation  in the MLR. The com- 
bination  of mAbs  to all three ICAMs completely  reduced 
100. 
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Figure  8.  Costimulatory effect of immobilized purified ICAM-3 and 
CD3 mAb. (A) Concentration dependence ofcostimulation. Various con- 
centrations of purified ICAM-3 and CD3 mAbs (OKT3) were coimmobi- 
lized before the addition of 5  x  104 resting T lymphocytes. (B) Costimu- 
lation is  mediated  by purified  ICAM-3  through  LFA-1 and  requires 
coimmobilized CD3 mAb. Purified ICAM-3 (1,400 site~/~a  z) and CD3 
mAb (1 mg/ml OKT3) were either coimmobilized  orCD3 mAb was only 
added in soluble form. Blocking mAbs were added at day 0 at a concentra- 
tion of 20/~g/ml. Proliferation responses in these cultures were measured 
by [3H]thymidine incorporation on day 3. One of three representative ex- 
periments is shown and bars show 1 SD. 
￿9  37 ~ 
[]  22 ~ 
[]  16 ~ 
[]  4  ~ 
ICAM-3 
Figure  7.  Effect  ofdivahnt cations and temper- 
ature  on  PMA-stimulated  SKW3  binding  to 
ICAM-1  and  ICAM-3.  (A)  SKW3  cells  were 
washed once and resusponded (2  ￿  104 cells/ml) 
in either (.4) Ca  2+-  and Mga+-free  HBSS con- 
ta~.ing the indicated concentrations  of MgClz, 
CaC12, or EDTA,  or  (/3)  assay buffer (PBS, 5% 
FCS, 2 mM MgCI2). SKW3 (2  x  106 cells) were 
then ~-~d~ to 60-mra petri dishes coated with spots 
of purified ICAM-1 and ICAM-3, and incubated 
for 60 min at either (.4) 37~  or (/3) the indicated 
temperature. Binding was measured as described 
in Fig. 3 legend. One of two (.4) or three (B) rep- 
resentative experiments is shown and bars show 
1 SD. 
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[]  ICAM-I+2+3  Figure 9.  Inhibition  of(A) PHA response and (B) 
Ag-specific proliferation by LFA-1, CD18,  ICAM-1, 
ICAM-2, and ICAM-3 mAbs. PHA response and Ag- 
specific response of freshly separated PBL were as de- 
scribed in Materials and Methods. In all assays mAbs 
were added at the start of the cell incubations  at final 
concentrations of 20/~g/ml. mAbs used were to LFA-1 
(TS1/22), CD18 (TS1/18), ICAM-1 (RR1/1), ICAM-2 
(CBR-IC2/2), and ICAM-3 (CBR-IC3/1 and CBR- 
IC3/2). One of either five (A) or three (B) representa- 
tive experiments is shown and bars show  I  SD. 
proliferation  to the levels seen with either stimulators  or 
responders alone. 
Last, all three ICAM mAbs were tested for their ability 
to inhibit HBsAg-dependent proliferation of  PBLs from vac- 
cinated, responding individuals (Fig. 9 B). Proliferation was 
inhibited by LFA-1 mAb to levels seen  in unstimulated PBLs. 
ICAM-1,  -2, and -3 mAbs showed slight inhibition when 
used separately, however, a combination ofmAbs to all three 
ICAMs reduced proliferation to levels seen in unstimulated 
PBL. 
Discunion 
In this study, we have functionally characterized the ICAM- 
3/LFA-1 interaction and investigated the relative roles of the 
ICAMs in immunological  responses. Purification of ICAM-3 
was achieved in a manner similar to that used in purifying 
ICAM-1. Alongside purified ICAM-3, cells were also tested 
for binding to purified ICAM-L Lymphoid cells adherent 
to both purified ICAM-1 and ICAM-3 had a spread mor- 
phology, indicative of cytoskeletal interactions (7, 49). This 
binding to purified ICAMs was completely inhibitable with 
anti-CD18  mAb,  indicating that  for both  ICAM-1  and 
ICAM-3, no additional ligands existed on lymphoid cells. 
Similarly, a leukocyte adhesion deficiency (LAD) patient- 
derived cell line, SLA, did not interact with either purified 
ICAM-1 or ICAM-3.  These cells expressed levels of CD43 
comparable to those of LFA-1; thus, we could not confirm 
ICAM-1  interaction with CD43 (45). Additionally, CD43 
mAbs, including those used in the previous study, had no 
effect on binding of lymphoid cells to either purified ICAM-1 
or ICAM-3. This is in agreement with previous studies in 
which mAbs  to  CDlla,  CDllb,  or  CD18,  or inherited 
deficiency of leukocyte integrins, have been found to abolish 
interactions of lymphoid cells and neutrophils, which express 
CD43, with ICAM-1 (11, 39, 50-52).  The interactions  of 
cells with purified ICAM-3 was cation and temperature de- 
pendent, similar to that described for purified ICAM-1 (11). 
The only difference was the lower overall binding of LFA-1- 
bearing cells to purified ICAM-3 than ICAM-1 at comparable 
site densities. This suggests that ICAM-3 has lower af~nity 
for LFA-1 than ICAM-1, consistent with results on the rela- 
tive contributions of ICAM-1 and ICAM-3 as LFA-1 ligands 
compared  with  their level of expression on different  cell 
lines (5). 
Binding of cells to both purified ICAM-1  and ICAM-3 
626  Function  of Intercellular  Adhesion Molecule 3 in Immune Responses was increased upon activation of LFA-1 adhesiveness. This 
result confirmed studies previously performed for ICAM-1 
(32, 47)  and extend them to include ICAM-3. Thus,  the 
binding site on LFA-1 for ICAM-1 and ICAM-3 is sufficiently 
similar to demonstrate low and high avidity states. Using 
purified LFA-3, we also confirmed the increased adhesive- 
ness of CD2 in response to phorbol esters (48). 
The CBR-IC3/1 mAb blocked binding of SKW3 cells to 
purified LFA-1, but not LFA-l-dependent PMA-induced cell 
aggregation,  or binding of LFA-l-bearing ceUs to purified 
ICAM-3. To fully characterize the role of ICAM-3 in im- 
munological responses, additional ICAM-3 mAbs were gener- 
ated. No single ICAM-3 was capable  of  completely inhibiting, 
in conjunction with mAbs to ICAM-1 and ICAM-2, SKW3 
aggregation or the binding of  SKW3 cells to purified ICAM-3. 
However,  a combination of two mAbs,  CBR-IC3/1  and 
CBR-IC3/2,  was  capable of completely inhibiting  these 
pathways  of adhesion. The epitopes  recognized by CBR/IC3/1 
and CBR-IC3/2 mAbs were determined by radioimmuno- 
assay to be distinct, and found to map to the first and second 
NH2-terminal  Ig-like domains of ICAM-3, respectively. As 
the LFA-1 binding site was found to localize solely to the 
NHz-terminal Ig-like domain (Klickstein,  L.,  A.  de Fou- 
gerolles, and T. Springer, manuscript in preparation),  it ap- 
pears that neither CBR-IC3/1 nor CBR-IC3/2 binds directly 
in the LFA-1 binding site, and a combination of two mAbs 
is required to sterically hinder binding to a nearby site. It 
appears that CBR-IC3/1 binds close to the LFA-1 binding 
site, however, because it inhibits  in assays in which LFA-1 
is immobilized on a substrate, although not in assays in which 
LFA-1 is present  on a cell surface. 
Two NH2-terminal Ig-like domain-specific  ICAM-3 mAbs 
(CBR-IC3/1  and CBR-IC3/6) dearly stimulate ICAM-3 + 
cells to aggregate in the absence of PMA. Other ICAM-3 
mAbs,  including some also recognizing the first NH2-ter- 
minal Ig-like domain, did not induce aggregation (de Fou- 
gerolles,  A.,  and  T.  Springer,  unpublished  results).  This 
aggregation was cation and temperature dependent, and was 
inhibited only by mAbs recognizing a different ICAM-3 epi- 
tope, one example being mAb CBR-IC3/2. Certain o~4 and 
/~1 mAbs are capable of inducing homotypic aggregation of 
lymphoid ceils in a similar manner (53-55). As with ol4 and 
B1 mAb-induced aggregation, Fab fragments of mAb CBR- 
IC3/1 were unable to induce aggregation.  Last, the CBR- 
IC3/1 mAb-induced aggregation was not reversible  with sub- 
sequent, as opposed to simultaneous, incubation with mAb 
CBR-IC3/2  (de FougeroUes, A., and T. Springer, unpub- 
lished results). Whether this aggregation represents evidence 
for  additional  ICAM-3  ligand(s),  signaling  through  the 
ICAM-3 molecule resulting in aggregation, or agglutination 
that synergizes with or stabilizes integrin-mediated homo- 
typic aggregation remains to be determined. 
Purified ICAM-3, when coimmobilized with CD3 mAb, 
provided a strong costimulatory signal for T cell prolifera- 
tion. The ability of ICAM-1 (24, 25), ICAM-2 (26), and 
now  ICAM-3,  when  ligated  with  LFA-1 to  provide  a 
costimulatory signal, indicates not only that the site recog- 
nized on LFA-1 is likely very similar, but also that the role 
of these molecules in immune responses may be dependent 
on their relative levels of expression on APC. Given the high 
level of ICAM-3, and to a lesser extent ICAM-2, expressed 
on monocytes and B lymphocytes (5), these molecules may 
support the activation of T cells. Their presence on APC may 
act as a means to deliver a costimulatory signal to TCR- 
engaged T lymphocytes, which might be especially impor- 
tant on ICAM-1- or ICAM-11~  APC before expression of 
ICAM-1  can be upregnlated. 
The  relative  contribution  of ICAM-1,  ICAM-2,  and 
ICAM-3 was examined in several  functional assays. In all three 
cases (PHA stimulation,  MLR, and antigen-specific presen- 
tation), inhibition was achieved with LFA-1 mAb, as previ- 
ously  reported  (42). mAbs  to  ICAM-1,  ICAM-2,  and 
ICAM-3, when used separately, resulted in partial inhibition. 
Consistent with these results are reports that ICAM-1 mAbs 
(8, 56, 57) and CD50 (ICAM-3)  mAbs (58) are capable of 
partially inhibiting immune responses. Complete inhibition 
was achieved  with a combination of mAbs to all three ICAM 
molecules, suggesting that ICAM-1, ICAM-2, and ICAM-3 
are the only LFA-1 ligands important in antigen-specific lym- 
phocyte responses. The importance of the LFA-1/ICAM inter- 
action in the initial phase of an immune response is under- 
scored  by the ability of LFA-1, ICAM-1, and CD50 (ICAM-3) 
mAbs to inhibit immune responses, and their inability to do 
so if added subsequent  to cell-cell conjugation (8,  58). 
ICAM-1  was  first  identified  in  1986 (9),  followed  by 
ICAM-2 in 1989 (3), and ICAM-3 in 1992 (5), based on evi- 
dence that previously identified ICAMs could not account 
for all of the ligand activity for LFA-1. Our results under- 
score the high degree of functional similarity and redundancy 
in the LFA-1 counter-receptors.  The three LFA-1 counter- 
receptors differ dramatically in inducibility and tissue distri- 
bution, suggesting specialization  for different cell interactions. 
Our study on ICAM-3, and previous ones on ICAM-1 (24, 
25) and ICAM-2 (26), show they induce similar costimuli 
in LFA-l-bearing cells; however,  signals induced by the ICAMs 
on the calls on which they are expressed may vary. The ability 
of a combination of mAbs to ICAM-1, ICAM-2, and ICAM-3 
to inhibit LFA-l-dependent adhesion of lymphoid cell lines, 
such as SKW3,  and three different T cell functions to the 
same extent as mAb to LFA-1, suggests that the most func- 
tionally important, and possibly all, of the ICAMs expressed 
on lymphocytes have now been defined. 
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